US FDA approves GSK's combo meningococcal vaccine
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
Hedge fund Citadel takes short position in GSK, FT reports
Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...
Here's Why We're Wary Of Buying GSK's (LON:GSK) For Its Upcoming Dividend
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might ...
FiercePharma8h
With new FDA approval, GSK joins Pfizer in the 5-in-1 meningococcal vaccine ring
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
Here’s the dividend forecast for GSK shares through to 2026!
City brokers expect dividends on GSK shares will keep marching higher. Is the FTSE 100 share a top passive income stock to ...
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive ...
GSK Pharma put volume heavy and directionally bearish
Pharma with 2,330 puts trading, or 1.1x expected. Most active are 2/14 weekly 36 puts and 2/28 weekly 36 puts, ...
The Financial Express22h
Q3FY25: GSK pharma’s profit surges 4X to Rs 229 crore; Revenue up 18 percent
In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines, the company ...
ndtvprofit22h
GSK Pharma Q3 Results: Profit Increases Fivefold, Beats Estimates
Glaxosmithkline Pharmaceuticals reported a profit of Rs 230 crore in third quarter, a 400% year-on-year jump from Rs 46 crore ...
Battle of the journals
Two Trump administration nominees with long track records of challenging the medical and public health establishments have ...
Citadel takes $384.5 million short position in GSK - FT
Citadel, the hedge fund owned by billionaire Ken Griffin, has taken a short position in GlaxoSmithKline (NYSE:GSK), a British ...
GSK Q3FY25 Results: Net profit jumps 4X to ₹229 crore; revenue improves 18%
GlaxoSmithKline Pharmaceuticals Ltd reported an 18% revenue increase to ₹946 crore for Q3 ended December 31, 2024, with a ...